Citigroup Maintains Buy on Summit Therapeutics, Lowers Price Target to $42
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.
